IRVINE, Calif.--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which runs February 17-19, 2021. Agendia Chief Executive Officer Mark Straley will participate in a fireside chat discussion on Thursday, February 18 at 11:00 AM EST.
A link to the live webcast of Mr. Straley’s presentation will be available by visiting the News & Updates section of Agendia’s website at https://agendia.com/news/. A replay of the webcast will be available on the Agendia website for 90 days following the conclusion of the live presentation broadcast.
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the most effective treatment decisions. The company currently offers two commercially-available genomic profiling tests, supported by clinical and real world evidence. MammaPrint®, the 70-gene breast cancer recurrence assay, and BluePrint®, the 80-gene molecular subtyping assay, provide a comprehensive genomic profile and the data physicians need to make more informed decisions in the pre- and post-operative treatment settings. By developing evidence-based novel genomic tests and conducting groundbreaking research while building an arsenal of data that will help treat cancer, Agendia aims to improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.